We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Juvenile Idiopathic Arthritis (JIA) is a type of arthritis that occurs in children, causing joint inflammation, pain, and stiffness. It can affect one or multiple joints and may lead to growth issues if not managed properly.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
